Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Target Review

MAY 1, 2024

How have advancements in antibody-drug conjugates (ADCs) expanded treatment options for different types of cancer? For example, enfortumab vedotin in combination with anti-PD-1 pembrolizumab reshaped the first-line treatment of patients with previously untreated metastatic urothelial cancer, doubling OS compared to standard of care.

Drugs 69

Drugs FDA Approval Organic Chemistry Small Molecule 69

The Open Targets Blog

SEPTEMBER 21, 2023

After completing my PhD in organic chemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. I then moved back to the UK to work as a process chemist at GSK, designing the manufacturing routes for small molecule drugs. I’m a chemist by training.

Organic Chemistry 82

Organic Chemistry Process Chemistry Small Molecule Science 82

Drug Target Review

MAY 31, 2024

Coupling my desire to be a scientist with my keen sense of adventure, I moved to Alaska out of high school to begin my undergraduate studies in chemistry, applying myself to my STEM classes whilst also climbing mountains and chasing Northern Lights.

Organic Chemistry 45

Organic Chemistry Computational Chemistry Small Molecule Disease 45